Millán CMA, Bautista BE, Santos MLE, Sandoval GJL

Language: Spanish
References: 30
Page: 71-77
PDF size: 69.60 Kb.

ABSTRACT

Background: Acute pulmonary embolism has a cardiovascular mortality rate of 15% to 20%. Patients with PE are very important differentiated who will has more risk of cardiovascular events. Methods and results: The present observational and prospective study included 22 patients with confirmed PE. Age 55 ± 15 years. We classificated in three groups: minor PE n = 9; PE + RVD n = 8; major PE n = 5. Elevated BNP › 500 pg/mL was significantly associated with mortality (P ‹ 0.001). The overall mortality was 18% and only in the major PE. Conclusions: The brain peptide natriuretic is a very important biomarker with a lot of utility in approach of patients with suspected pulmonary embolism.

REFERENCES

1. British Thoracic Society Guidelines for the management of suspected acute pulmonary embolism. Thorax 2003; 53: 470-484.

2. Guidelines on diagnosis and management of acute pulmonary embolism. European Heart Journal 2000: 1301-1336.

3. Zippes D, Libby P, Bonow R, Braunwald E. Heart disease. Textbook of cardiovascular medicine. 7a Ed. USA. Elsevier Saunders. 2005: 1789.

4. Karwinski B, Suendsen E. Comparison of clinical and post mortem diagnosis of pulmonary embolism. J Clin Pathol 1989; 42(2): 135-9.

5. De Jesus Villagomez, Alcantar L, Avelar F, Ayala L; Bautista B. Guías para el Diagnóstico, Prevención y Tratamiento de la Enfermedad Tromboembólica Venosa. Revista del Colegio de Medicina Interna de México. 2006; 22 supl.1.

6. Pieralli F, Olivotto I, Vanni S. Usefulness of bedside testing for brain natriuretic peptide to identify right ventricular dysfunction and outcome in normotensive patients with acute pulmonary embolism. Am J Cardiol 2006; 97: 1386-1390.

7. Mills R. Measurement of B type natriuretic peptide in clinical practice: A critical appraisal. J Am Coll Cardiol Posted 12/03/2002.

8. ten Wolde M, Tulevski I, Molder J. Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation 2003; 107: 2082-2084.

9. Sohne M, ten Wolde M, Buller H. Biomarkes in pulmonary embolism. Curr Opin Cardiol 2004; 19: 558-562.

10. Konstantinides S, Geibel A, Olschewski M. Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation 2002; 106: 1263-1268.

11. Metha N, Ketan J, Khan I. Clinical usefulness and prognostic value of elevated cardiac troponin I leves in acute pulmonary embolism. Am Heart J 2003; 145: 821-5.

12. Meyer T, Binder L, Hruska N. Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dysfunction. J Am Coll Cardiol 2002; 36: 1632-1636.

13. Horlander K, Leeper K. Troponin levels as a guide to treatment of pulmonary embolism. Curr Opin Pulm Med 2003; 9: 374-377.

14. Kucher N, Printzen G, Goldhaber S. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 2003; 107: 2545-2547.

15. Kline J, Hernandez-Nino J, Rose G. Surrogate markers for adverse outcomes in normotensive patients with pulmonary embolism. Crit Care Med 2006; 34: 2773-2780.

16. King L, Wilkins MR, et al. Natriuretic receptors an the heart. Heart 2002; 87: 314-316.

17. Bin Y, Mukerjee D, Timms P. Natriuretic peptides respiratory disease, and the right heart. Chest 2004; 126: 1330-1336.

18. Kruger S, Graf J, Merx M. Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism. Am Heart J 2004; 147: 60-5.

19. AlMahameed A, Bartholomew R. Patients with acute pulmonary embolism should have an echocardiogram to guide treatment decision. Med Clin N Am 2003; 87: 1251-1262.

20. Hung-Hsiao, Lee C, Chang S. Pulmonary embolism and right heart function: insights from myocardial Doppler tissue imaging. J Am Soc Echocardiogr 2006; 19: 822-828.

21. Kjaergaard J, Krogsgaard B, Lund J. Quantitative measures of right ventricular dysfunction by echocardiography in the diagnosis of acute non massive pulmonary embolism. J Am Soc Echocardiogr 2006; 19: 1264-1271.

22. Kucher N, Goldhaber S. Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. Circulation 2003; 108: 2191-2194.

23. Lang R, Bierig M, Devereux R, et al. Recommendations for chamber quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group. J Am Soc Echocardiogr 2005; 18: 1440-1463.

24. Kurzyna M, Torbicki A, Pruszczyk P. Disturbes right ventricular ejection pattern as a new Doppler echocardiographic sign of acute pulmonary embolism. Am J Cardiol 2002; 90: 507-511.

25. Giannitsis E, Katus H. Risk stratification in pulmonary embolism based on biomarkers and echocardiography. Circulation 2005; 112: 1520-1521.

26. Kluetz P, White C. Acute pulmonary embolism: Imaging in the Emergency Department. Radiol Clinics N Am 2006; 44: 259-71.

27. Piazza G, Goldhaber S. Acute pulmonary embolism. Circulation 2006; 114: e42-e47.

28. Ferrari E, Imbert A, Chevalier T, et al. The ECG in pulmonary embolism: Predictive value of negative T waves in precordial leads- 80 case reports. Chest 1997; 111(3): 537-543.

29. Ullman E, Brady W, Perron A, et al. Electrocardiographic manifestation of pulmonary embolism. American Journal of Emergency Medicine 2001; 19(6): 514-519.

30. Santos ME. Disfunción ventricular derecha en tromboembolia pulmonar. Neumología y Cirugía de Tórax 2005; 64: 63-71.